Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

UK JCVI Not Recommends Novartis's Meningitis B Vaccine Bexsero For Immunization

RELATED NEWS
Trade NVS now with 

Swiss drug maker Novartis AG (NVS: Quote), Wednesday said the UK Joint Committee on Vaccination and Immunisation or JCVI took an interim position to not recommend Bexsero vaccine for inclusion in the National Immunisation Programme, driven by evaluation based on cost-effectiveness assumptions. The company added that the JCVI does not feel that the decision is in the interest of the public.

Novartis said the JCVI made its evaluation before any pricing discussion with it and if the position is not changed, it will postpone Bexsero access.

In January 2013, the European Medicines Agency licensed Bexsero for active immunization of individuals from two months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.

Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Personal spending in the U.S. unexpectedly decreased in the month of September, according to a report released by the Commerce Department on Friday, with the drop in spending accompanied by weaker than expected personal income growth. Stocks are likely to jump sharply at the start of trading on Friday, extending the upward move seen over the course of the previous session. The major index futures are currently pointing to a substantially higher open for the markets, with the Dow futures up by 169 points. Eurozone inflation rose slightly in October but it remained consistently below 1 percent, signifying the risk of deflation in the currency bloc. At the same time, the unemployment rate held steady at an elevated level in September. Inflation rose marginally to 0.4 percent in October from 0.3 percent in September, flash data from Eurostat showed Friday.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.